On December 12, 2021, based on the GEMSTONE 302 trial (NCT03789604), sugemalimab was approved in China for the first-line treatment of EGFR/ALK-negative mNSCLC in combination with pemetrexed and carboplatin for non-squamous NSCLC, and in combination with paclitaxel and carboplatin for squamous NSCLC (13, 14). Here, EGFR is linked to non-small cell lung carcinoma.